Race to stop clots: drug dose tested to keep ICU kidney filters flowing
NCT ID NCT07469072
Summary
This study aims to find the best dose of a blood-thinning drug (Nafamostat) for ICU patients whose kidneys have failed and need continuous dialysis. Researchers will compare a low dose to a high dose to see which one helps the dialysis filter last longer without dangerous clotting or bleeding. The main goal is to improve the safety and effectiveness of this life-supporting treatment for 92 critically ill patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Critical Care Medicine of Zhujiang Hospital,Southern Medical University
Guangzhou, Guangdong, 510282, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.